Does combined use of drugs with higher plasma-protein binding degree necessarily lead to clinically significant interactions?

Yao Wenxin, Liu Wei, Liu Zhijun

PDF(788 KB)
PDF(788 KB)
Adverse Drug Reactions Journal ›› 2019, Vol. 21 ›› Issue (4) : 285-289. DOI: 10.3760/cma.j.issn.1008-5734.2019.04.008

Does combined use of drugs with higher plasma-protein binding degree necessarily lead to clinically significant interactions?

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2019, 21(4): 285-289 https://doi.org/10.3760/cma.j.issn.1008-5734.2019.04.008

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(788 KB)

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉